semaglutide approved for cardiovascular The weight-loss drug Wegovy lowered heart attack risk in a large trial Oral Semaglutide Approved to Reduce

Inflammation, cancer and oxidative lipoxygenase activity are intimately linked

Novo and its biggest rival in the obesity drug market, Eli Lilly, sued several medical spas, weight-loss clinics and compounding pharmacies last year to stop them from selling products purporting to contain the active ingredients

While more research is needed, the safety profile of GLP-1 agonists in treating diabetes and obesity offers hope for their future use in addiction therapy

Ozempic primarily works with the pancreas by enhancing insulin release and reducing excess sugar production

Walsh D, Kirkova J, Davis MP

For long-term heart health, maintaining optimal glutathione levels may help reduce your risk of serious cardiovascular events